United States
OxyBand Technologies, Inc. is a pioneering company in the health care and medical devices industries, founded in 2003 and headquartered in the United States. The company has garnered significant attention and investment, with its last funding round amounting to a substantial $700.00K in a Series A investment on 23 March 2010.
OxyBand Technologies stands out due to its groundbreaking OxyBand™ wound dressing, which is the only FDA-approved dressing capable of delivering pure oxygen to damaged tissue continuously for up to 5 days. Clinical trials, including research conducted by the United States Army Institute for Surgical Research, have demonstrated the remarkable efficacy of OxyBand™, showcasing accelerated healing and reduced pain without any infection when compared to standard care.
Moreover, the company's focus on developing proprietary patented biomedical technologies for various applications, including traumatic and acute wounds, diabetic ulcers, eye diseases, orthopedics, and regenerative medicine, highlights its potential for impact across diverse medical fields.
